Clinical trials: Regorafenib
Rectal Adenocarcinoma, Stage IIA Rectal Cancer
Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
This phase II trial studies how well regorafenib works in reducing the return of disease in patients with rectal cancer that has not spread to another place in the body who have completed curative-intent treatment.
- Conditions
- Rectal Adenocarcinoma, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer
- Trial name
- NCT02287727
- Testing
- Laboratory Biomarker Analysis, Regorafenib
- Where
- 3 sites in United States
- Sponsor
- Roswell Park Cancer Institute
Intrahepatic Cholangiocarcinoma
HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC
This study is a single-arm Phase II clinical trial aiming to evaluate the safety and efficacy of HAIC combined with Cadonilimab and Regorafenib as second-line treatment for unresectable intrahepatic cholangiocarcinoma.
- Trial name
- NCT06335927
- Testing
- HAIC-GEMOX+Cadonilimab+Regorafenib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Colorectal Neoplasms, Metastatic Disease
Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
The purpose of this study is to assess the efficacy of single-agent regorafenib in the second-line treatment in metastatic colorectal cancer with any RAS or BRAF mutation previously treated with FOLFOXIRI plus bevacizumab in…
- Trial name
- PREVIUM (NCT02175654)
- Testing
- Regorafenib
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Advanced Cancer
A Study of CS1003 in Subjects With Advanced Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as CS1003 in patients with advanced tumors.
- Trial name
- NCT03475251
- Testing
- CS1003, Regorafenib
- Where
- Australia
- Volunteers
- 108 people
- Sponsor
- CStone Pharmaceuticals
Metastatic Colorectal Cancer
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
This is a randomized, double-blind, placebo-controlled multi-center phase III study to evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved…
- Trial name
- NCT01103323
- Testing
- Regorafenib (Stivarga, BAY73-4506), Best Supportive Care (BSC)
- Where
- 171 sites in United States, Argentina and 17 more
- Volunteers
- 760 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy
This is a single centre prospective biological translational research study involving the collection of tumour tissue, blood samples and clinical data from patients being treated with regorafenib for metastatic Colorectal Cancer…
- Trial name
- PROSPECT-R (NCT03010722)
- Testing
- Regorafenib
- Where
- United Kingdom
- Volunteers
- 49 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Colorectal Cancer
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
A prospective, multicenter, randomized in a 2:1 ratio, controlled, clinical trial with two parallel arms will be conducted to compare irinotecan dose escalated FOLFIRI according to UGT1A1 genotyping plus 120 mg regorafenib with…
- Trial name
- NCT03880877
- Testing
- Regorafenib, UGT1A1 genotyping (TA6/TA6), UGT1A1 genotyping (TA6/TA7)
- Where
- Taiwan
- Volunteers
- 153 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Liposarcoma, Osteogenic Sarcoma
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and/or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other…
- Conditions
- Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcoma, Rhabdomyosarcoma
- Trial name
- NCT02048371
- Testing
- Regorafenib
- Where
- 18 sites in United States
- Volunteers
- 131 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Advanced Hepatocellular Carcinoma (HCC)
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of Camrelizumab Combined with Rivoceranib Mesylate versus Investigator's Choice of Regimen in Treatment of…
- Trial name
- NCT04985136
- Testing
- camrelizumab；Rivoceranib, Rivoceranib, Sorafenib
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gastric Cancer
Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer
Randomized, double-blind, placebo-controlled, multicenter Phase-II study. Approximately 120 subjects with CR/PR/SD after platinum compounds and fluoropyrimidines based regimens: up to 6 cycles of cisplatin and 5-fluorouracil or…
- Trial name
- a-MANTRA (NCT03627728)
- Testing
- Regorafenib
- Where
- Italy
- Volunteers
- 67 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Gastrointestinal Stromal Tumors
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.
- Trial name
- NCT01646593
- Testing
- Regorafenib (BAY73-4506)
- Sponsor
- Bayer
Advanced Refractory Solid Tumors
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
This is a multicenter, open-label study of CS1001 in combination with regorafenib in participants with advanced or refractory cancers.
- Trial name
- NCT04200404
- Testing
- CS1001, Regorafenib
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- CStone Pharmaceuticals
Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase Ib trial tests the safety, side effects, best dose and effectiveness of regorafenib in combination with venetoclax and azacitidine in treating patients with acute myeloid leukemia (AML) that has come back after a…
- Conditions
- Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
- Trial name
- NCT06454409
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer
Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer
This study intends to perform high-intensity focused ultrasound combined with REGOTORI in patients with multiline drug-resistant metastatic colorectal cancer to explore the safety and efficacy of patients.
- Trial name
- NCT04819516
- Testing
- high-intensity focused ultrasound therapy, Toripalimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Liver Neoplasms
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)
- Trial name
- NCT03289273
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 37 sites in United States, Argentina and 19 more
- Volunteers
- 1,010 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer
This was a phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer.
- Trial name
- NCT03081494
- Testing
- spartalizumab (PDR001), regorafenib
- Where
- 11 sites in Australia, Canada and 6 more
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Solid Cancer
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed.
- Trial name
- NCT03890731
- Testing
- BAY73-4506 (Regorafenib, Stivarga)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 6 people
- Sponsor
- Bayer
Solid Tumors
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.
- Trial name
- NCT04704154
- Testing
- Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Where
- 34 sites in United States, Belgium and 6 more
- Volunteers
- 175 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.
- Trial name
- ARC-9 (NCT04660812)
- Testing
- AB680, Etrumadenant, Zimberelimab
- Where
- 44 sites in United States, France and 4 more
- Volunteers
- 227 people
- Sponsor
- Arcus Biosciences, Inc.
Gastrointestinal Stromal Tumors, Metastasis
Salvage Surgery for Patients With Metastatic GIST With Rego
Some researches have shown surgery may acquire progression-free (PFS) benefit for selected patients with metastatic gastrointestinal stromal tumor (GIST) who received first-line imatinib and second-line sunitinib.
- Conditions
- Gastrointestinal Stromal Tumors, Metastasis, Disease Progression
- Trial name
- NCT04343456
- Testing
- Salvage surgery with massive debulking
- Where
- Taiwan
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital